Copyright © Inderes 2011 - present. All rights reserved.

Nexstim

8,2

 

EUR

 

-4,65 %

Corporate customer

NXTMH

First North Finland

Medical Equipment & Services

Health Care

5.296 investorer følger denne virksomhed
Sammenligne
-4,65%
+62,06%
+121,62%
+176,09%
+178,91%
+233,33%
+82,63%
+250,98%
-98,65%

Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.

Læs mere
Markedsværdi
58,73 mio. EUR
Aktieomsætning
221,47 t EUR
P/E (adj.) (24e)
-606,37
EV/EBIT (adj.) (24e)
18.722,76
P/B (24e)
15,57
EV/S (24e)
6,47
Udbytteafkast, % (24e)
-
Coverage
Anbefaling
Akkumulér
Kursmål
6.20 EUR
Opdateret
02.12.2024
Disclaimer
Latest research

Latest analysis report

Released: 02.12.2024

Latest extensive report

Released: 06.10.2023

Finanskalender
27.2
2025

Årsrapport '24

Risiko
Business risk
Valuation risk
Lav
Høj
ViserAlle indholdstyper

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Analyse af
Antti Siltanen

Nexstim: Further evidence of cash flow turnaround

Nexstim's year of surprises continued on Friday when the company announced a new development and distribution cooperation agreement with Germany's Brainlab AG. The agreement will strengthen Nexstim's financial position and improve its performance starting next year.

Nexstim
Business news update from Nexstim
Analytikerkommentar af
Antti Siltanen

Business news update from Nexstim

Nexstim issued a press release on business highlights for January-September. The company said it has invested in profitable growth, development of its NBS 6 diagnostics product and expansion of its network of clinics.

Nexstim
Analyse af
Antti Siltanen

Nexstim: Taking a breather after handsome returns

On Friday, Nexstim announced that it had obtained a license in India, which means an authorization to sell the NBS5 system in a new market. We raised our medium- and long-term forecasts based on the new market opening, although the visibility of the Indian market is very limited.

Nexstim
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.